Urinary biomarkers of non-muscle-invasive bladder cancer: Current status and future potential

Daniele Calistri, Valentina Casadio, Sara Bravaccini, Wainer Zoli, Dino Amadori

Research output: Contribution to journalArticlepeer-review

Abstract

Bladder cancer diagnosis and patient surveillance present a wide range of diagnostic methods but essentially only instrumental approaches are available in the clinical setting. Although numerous new noninvasive biomarkers have been proposed in the last 10 years, few are US FDA-approved for clinical purposes, and none are widely used in routine clinical practice. In this review, we summarize the tests developed for early diagnosis and patient surveillance and verify whether, for any, there is some level of evidence to suggest a real usefulness in a clinical setting.

Original languageEnglish
Pages (from-to)743-752
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2012

Keywords

  • early diagnosis
  • epigenetic
  • FDA marker
  • FISH
  • gene mutation
  • immunoassay
  • molecular marker
  • noninvasive bladder tumor
  • surveillance
  • urine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Urinary biomarkers of non-muscle-invasive bladder cancer: Current status and future potential'. Together they form a unique fingerprint.

Cite this